Seoulin Bioscience Q1 2026: Profitability Weakens but Financial Stability Remains
Consolidated Q1 2026: Revenue 19.5B won, OP 0.18B won, NP 0.15B won. Operating profit declined sharply YoY (standalone OP from 0.4B to 0.04B).
Debt ratio 39.93%, net debt ratio -26.88% indicating strong financial health. Cash and short-term financial instruments 34.8B won.
Maintained cash dividend for 24 consecutive years and stock dividend for 17 years. For 2025, cash dividend of 100 won per share and stock dividend of 200,000 shares approved.
Potential dilution from 15B won CB (conversion price 6,261 won) and 3.3B won EB (exchange price 7,771 won) issued in 2025.
New businesses (health functional foods, alternative meat, logistics) are in R&D stage and not yet contributing to profit.